Clinical Trial: Clarithromycin v Ciprofloxacin Added to Rifampicin + Ethambutol, for Opportunist Mycobacterial Pulmonary Disease
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: Treatment of Pulmonary Disease Caused by MAIS, M.Xenopi or M.Malmoense: A Comparison of Two Triple Drug Regimens and an Assessment of the Value of Immunotherapy With M.Vac
Brief Summary: To date key drugs in the treatment of MAIS, M.malmoense and M.xenopi (Opportunist Mycobacteria have been rifampicin and ethambutol. Clarithromycin and Ciprofloxacin are active in vitro against these species of mycobacteria. The primary aim of this study was to compare these to agents as supplements to rifampicin and ethambutol. A secondary aim was to assess the vale of immunotherapy with M.vaccae.
Detailed Summary:
Sponsor: British Thoracic Society
Current Primary Outcome:
- Death rates
- Cure rates
- Relapse rates
- Unwanted effects of therapy
Original Primary Outcome: Same as current
Current Secondary Outcome: Benefit or not of immunotherapy with M.vaccae
Original Secondary Outcome: Same as current
Information By: British Thoracic Society
Dates:
Date Received: August 21, 2006
Date Started: March 1995
Date Completion: September 2004
Last Updated: August 21, 2006
Last Verified: July 2006
